The estimated Net Worth of Pharmaceutical Co., Ltd. Senju is at least $962 mil dollars as of 29 January 2018. Pharmaceutical Senju owns over 100,000 units of Eyenovia Inc stock worth over $962,397 and over the last 7 years Pharmaceutical sold EYEN stock worth over $0.
Sign up
Pharmaceutical Senju EYEN stock SEC Form 4 insiders trading
Pharmaceutical has made over 1 trades of the Eyenovia Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Pharmaceutical bought 100,000 units of EYEN stock worth $1,000,000 on 29 January 2018.
The largest trade Pharmaceutical's ever made was buying 100,000 units of Eyenovia Inc stock on 29 January 2018 worth over $1,000,000. On average, Pharmaceutical trades about 100,000 units every 0 days since 2018. As of 29 January 2018 Pharmaceutical still owns at least 1,718,566 units of Eyenovia Inc stock.
You can see the complete history of Pharmaceutical Senju stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Pharmaceutical Senju's mailing address?
Pharmaceutical's mailing address filed with the SEC is 501 5th Ave #1404, New York, NY 10017, USA.
Insiders trading at Eyenovia Inc
Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant, eFredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.
What does Eyenovia Inc do?
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
What does Eyenovia Inc's logo look like?
Complete history of Pharmaceutical Senju stock trades at Eyenovia Inc
Eyenovia Inc executives and stock owners
Eyenovia Inc executives and other stock owners filed with the SEC include:
-
Tsontcho Ianchulev,
Chief Executive Officer, Director, Chief Medical Officer -
Dr. Tsontcho Ianchulev M.P.H., M.D., MPH,
CEO, Pres, Chief Medical Officer & Director -
John Gandolfo,
Chief Financial Officer, Secretary -
John P. Gandolfo CPA,
CFO & Sec. -
Michael Rowe,
Vice President - Commercial -
Jennifer Clasby,
Vice President - Clinical Operations -
Michael M. Rowe,
Chief Operating Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Tram Bui,
IR Contact Officer -
Anthony Sun,
Independent Director -
Charles Mather,
Independent Director -
Ernest Mario,
Independent Director -
Kenneth Lee,
Independent Director -
Curt Labelle,
Director -
Luke Clauson,
Vice President - Research &Development and Manufacturing -
Norbert Lowe,
VP of Sales & Marketing -
Alexander Lobo,
Investor Contact -
Andrew D. Jones,
Chief Financial Officer -
Julia A Haller,
-
Bren Kern,
Chief Operating Officer -
Pharmaceutical Co., Ltd. Senju,
10% owner -
Shuhei Yoshida,
Director -
Stuart M. Grant,
-
Stephen Keith Benjamin,
-
Rachel Jacobson,
Director -
Ellen R Strahlman,
Director -
Michael S Geltzeiler,
Director -
Ram Palanki,
Director